heroin addiction & related clinical problems

November 19-21, 2021

Heroin Addiction &Related Clinical Problems

European Opioid Addiction Treatment Association - EUROPAD

1414thth European Congress European Congress

World Trade Center Grenoble5-7, place Robert Schuman - BP 1521

38025 GRENOBLE CEDEX 1Phone +33 476 28 28 82

WWW.CONGRES-WTCGRENOBLE.COM

University of Grenoble

GRENOBLEFRANCE-EU

www.europad.org; www.europadevents.org; www.heroinaddictionrelatedclinicalproblems.orgwww.europad.org; www.europadevents.org; www.heroinaddictionrelatedclinicalproblems.org

CoordinatorsIcro Maremmani (Pisa, Italy) Maurice Dematteis (Grenoble, France)Marc Reisinger (Brussels, Belgium) Andrej Kastelic (Ljubljana, Slovenia)

Local Scientific CommitteeMichel Mallaret (Grenoble, France) Lucie Pennel (Grenoble, France)Georges Brousse (Clermont-Ferrand)

International Scientific Committee

European OpioidAddiction Treatment Association

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The visionEUROPAD exists to improve the lives of non-medical users and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opioid addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide

Scientific Committee of GRENOBLE2021EUROPAD

Adrian-Octavian Abagiu (Bucarest, Romania)Hannu Alho (Helsinki, Finland)Marc Auriacombe (Bordeaux, France)Alexander Baldacchino (St Andrews, Scotland, UK)Barbara Broers (Geneve, Switzerland)Miguel Casas (Barcelona, Spain)Thomas Clausen (Oslo, Norway)Michael Farrell (Sydney, New South Wales, Australia)Loretta Finnegan (Satellite Beach, Florida, USA)Gabriele Fischer (Vienna, Austria)Carla Gambarana (Siena, Italy)Gilberto Gerra (UNODC)Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)Milazim Gjocjaj (Pristina, Kosovo)Liljana Ignjatova (Skopje, Macedonia)Ante Ivancic (Porec, Croatia)Minja Jovanovic (Kragujevac, Serbia)Alexander Kantchelov (Sofia, Bulgaria)Alexander Kozlov (Moscow, Russia)Evgeny Krupitsky (St. Petersburg, Russia)

Mercedes Lovrecic (Ljubljana, Slovenia)Angelo G. I. Maremmani (Viareggio, Italy)Garrett McGovern (Dublin, Ireland)Haim Mell (Jerusalem, Israel)Vladimir Mendelevich (Kazan, Russia)Genci Mucullari (Tirana, Albania)Lubomir Okruhlica (Bratislava, Slovak Republic)Mark Parrino (Ney York, New York, USA)Matteo Pacini (Pisa, Italy)Luis Patricio (Lisbon, Portugal)Einat Peles (Tel Aviv, Israel)Giulio Perugi (Pisa, Italy)Jens Reimer (Hamburg, Germany)Roncero Alonso Carlos (Salamanca, Spain)Lorenzo Somaini (Biella, Italy)Marta Torrens (Barcelona, Spain)Touzeau Didier (Paris, France)Albrecht Ulmer (Stuttgart, Germany)Peter Vossenberg (Deventer, The Netherlands)Stephan Walcher (Munich, Germany)

Organizing CommitteeTi.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy

Phone +39 0564412038 - Fax +39 0564412485E-mail: [email protected]

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, ItalyPhone +39 0584790073 - Fax +39 058472081

E-mail:[email protected]

Under the Patronage of

World Federation for the Treatment of Opioid Dependence, New York, NY, USANGO with Special Consultative Status with United Nations Economic and Social Counsil (ECOSOC)

University of Grenoble, Grenoble, France, EUFédération Française d’Addictologie

Mission interministérielle de lutte contre les drogues et les conduites addictives Féderation Addiction

Promoted by

European Opioid Addiction Treatment Association, Pisa, Italy, EU

Association for the Application of Neuroscientific Knowledge to Social Aims, Pietrasanta, Italy, EU

Pisa School of Experimental and Clinical Psychiatry, Pisa, Italy, EU

Congress PresidentsMAURICE DEMATTEIS (Grenoble, France, EU)

ICRO MAREMMANI (Pisa, Italy, EU)

Local Scientific CommitteeGeorges Brousse (Clermont-Ferrand, France, EU)

Michel Mallaret (Grenoble, France, EU)Lucie Pennel (Grenoble, France)

Venue

World Trade Center Grenoble5-7, place Robert Schuman - BP 1521

38025 GRENOBLE CEDEX 1Phone +33 476 28 28 82

WWW.CONGRES-WTCGRENOBLE.COM

Grenoble, France, November 19-21, 2021


- 3 -

PROGRAM

FRIDAY NOVEMBER 19, 2021Room

and timeABSTRACT

No

Plenary Room ⃝⃝ ORAL PRESENTATIONS

⃝ Europad Oral PresentationsChair: Angelo G. I. Maremmani (Viareggio, Italy, EU)

9:00 OP-1MARC AURIACOMBE (Bordeaux, France, EU) - Substance Use Disorder Diagnosis and Craving: Comparison of Substance Users Accessing Treatment and Substance Users in Harm Reduction Programs.

9:20 0P-2ROSHAN BHAD (New Delhi, India) - A Study of Pathways to Care, Stigma and Clinical Correlates of Treatment Seeking Natural Opioid Users in India: Implications for Opioid Crisis Management

9:40 0P-3 PETER ESPENSHADE (Montpellier, USA) - Neither Necessary nor Sufficient, the Role of Peers in the Recovery Workforce

10:00 OP-4 ZOZAN GULEKEN (Istanbul, Turkey) - Spectroscopy and Computer Based Analyse May Be a Tool for Early Diagnose of Inflammation for Opioid Use Disorder Patients

10:20 OP-5 ZUZANA KAMENDY (Bratislava, Slovakia) - Burnout Syndrome in Health Care Professionals in Addiction Treatment

10:40 OP-6 SORAYA MAYET (Hull, UK) - Tele-medicine in Addictions Randomised Controlled Trial

11:00 OP-7LUCIE PENNEL (Saint-Martin d’Hères, France, EU) - Buprenorphine as a Last Resort Medication for Severe and Treatment Resistant Alcohol-Use Disorder: An Observational Compassionate Study

11:20 OP-8PERRINE ROUX (Marseille, France, EU) - Individualized Medicine in Harm Reduction : A Step Forward in the Treatment of Addiction

11:40 OP-10 ALBRECHT ULMER (Stuttgart, Germany, EU) - Dihydrocodeine Vs. Acamprosate for the Medical Adjustment of Alcohol Dependent Patients

FRIDAY NOVEMBER 19, 2021Room and

timeABSTRACT

No

PlenaryRoom ⃝ EUROPAD PRE-CONGRESS SYMPOSIUM

1 - INTERNET PROBLEMATIC USE IS ASSOCIATED WITH PSYCHOPATHOLOGY SPECIFIC OF SUBSTANCE USE DISORDERChair: Liljana Ignjatova (Skopje, North Macedonia)

12:00 SE1-1 LILJANA IGNJATOVA (Skopje, North Macedonia) - Problematic Internet Use Among Youngsters

12:20 SE1-2 CATERINA FLORA (Paphos, Cyprus, EU) - European Network For Problematic Internet Use: Citizens Involvement. A Pilot Study In Parents, In Greece

12:40 SE1-3 FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Internet Problematic Use Is Associated with Psychopathology Specific of Substance Use Disorder

PlenaryRoom ⃝ EUROPAD LUNCH SPECIAL CONFERENCE

FRONTIERS IN ADDICTION MEDICINEChair: Icro Maremmani (Pisa, Italy, EU)

13:00 SE2-1 MARC REISINGER (Brussels, Belgium, EU) - Climate Anxiety and Addictive Behaviours

EUROPAD SPECIAL EVENTSPlenaryRoom ⃝ EUROPAD SPECIAL CONFERENCE funded by industry

1 - LEVO-METHADONE IN ITALYChair: Icro Maremmani (Pisa, Italy, EU)

13:30 SE3-1 MARCO RIGLIETTA (Bergamo, Italy, EU) - LEVOPROACT: post-marketing surveillance in Italy

PlenaryRoom ⃝ SPECIAL EVENTS funded by industry

2 - SHIFTING PARADIGMS: CLINICAL EXPERIENCE OF LONG-ACTING FORMULATIONS Chair: Icro Maremmani (Pisa, Italy, EU)

14:00 SE4-1 ICRO MAREMMANI (Pisa, Italy, EU) - Is the Agonist Opioid Treatment Long Enough? The Role of Long-acting Medications

14:20 SE4-2 LORENZO SOMAINI (Biella, Italy, EU) - Understanding long-acting formulations

14:40 SE4-3 ARUN DHANDHAYUDHM (London, UK) - Experience of using long-acting formulations in UK

15:00 SE4-4 DAN LUBMAN (Richmond, Victoria, Australia) - Experience of using long-acting formulations in Australia 3 - BEYOND THE PILL: FUTURE DIRECTIONS IN THE TREATMENT OF OPIOID USE DISORDER (OUD)Chair: Lorenzo Somaini (Biella, Italy, EU)

15:30 SE5-1 LORENZO SOMAINI (Biella, Italy, EU) - Moving Towards an Evidence Based Approach in OUD

16:00 SE5-2 LUKE MITCHESON (London, UK) - Improving patient outcomes through effective PSIs16:30 SE5-3 MARK GILMAN (Manchester, UK) - A holistic approach to optimising patient recovery



- 4 -

FRIDAY NOVEMBER 19, 2021ABSTRACT

PlenaryRoom ⃝ PLENARY SESSION 1

Chair: Icro Maremmani (Pisa, Italy, EU) - Maurice Dematteis (Grenoble, France, EU)

17:15 ICRO MAREMMANI (Pisa, Italy, EU) & MAURICE DEMATTEIS (Grenoble, France) - Conference Opening

17:30 PL-1MARK PARRINO (New York, NY, USA) - Evolving Policy Issues with Opioid Use Disorder in the United States

18:00 PL-2Sir JOHN STRANG (London UK) - Treatment of Opioid Use Disorder: Three Lessons to Learn from the Past and Changes We Must Make for a Better Future

19:00 PL-3MAURICE DEMATTEIS (Grenoble, France, EU) - From Categories to Dimensions in Addiction Medicine and Mental Health: A Pragmatic Approach to Treat Patients from Harm Reduction to Recovery

20:00 BREAK

20:30 ⃝Welcome Cocktail and EUROPAD Chimera AWARD 2020- The Alessandro Tagliamonte AwardChairs: Icro Maremmani (Pisa, Italy, EU) - Marc Reisinger (Brussels, Belgium, EU) Andrej Kastelic (Ljubljana, Slovenia, EU)To be awarded: STEPHAN WALCHER (Munich, Germany) GENCI MUCOLLARI (Tirana, Albania) ANGELO G.I. MAREMMANI (Viareggio, Italy) Career Award: HERMAN JOSEPH (New York, NY, USA) - To memory

21:30

CONCERT IN HONOUR OF ROBERT NEWMANRobert-Newman-Trio, a composition of Albrecht UlmerAndrey Khvostenko, violinMarcin Niziol, violaAlbrecht Ulmer, piano forte

Dr. Robert Newman (1937 - 2018) was like a good father and friend for many of us. He was the former president of the Beth Israel Medical center in New York, where the Methadone maintenance therapy was developed by Mary Nyswander and Vincent Dole. Later, from 2001–2013, he worked as director of the Baron Edmond de Rothschild Chemical Dependency Institute of BIMC. He counseled innumerable experts and governments whole over the world how to implement the treatment with Methadone. Many called him “Methadone-pope”, and he joked: I’m the only Jewish pope of the world. He was a real and personal friend for many of us. This is specially to mention towards Germans, because his grandfather Feilchenfeld was killed in a concentration camp by the Nazis (Feilchenfeld-subject in the final movement of the trio). But Robert was one of most wise persons of the world, never asking for any guilt, but interested in everybody, always open for a warm hearted friendship. He never asked: How important is this person for me? He encouraged many of us, who elsewhere experienced several disregards from leading experts, because they where no leading or established persons. His sensibility for the dignity of broken and especially addicted patients was unique. Many of us are influenced by this particular humanity in our daily work with the addicted patients for ever.



- 5 -

SATURDAY NOVEMBER 20, 2021Room

and timeABSTRACT

No

9:00 ⃝ PARALLEL SYMPOSIA

PlenaryRoom ⃝

1 - PAIN PSYCHIATRIC DISORDERS AND ADDICTIVE DISORDERS: GROWING EPIDEMIOLOGY AND COMMON PATHOPHYSIOLOGY PLEAD FOR INTEGRATED APPROACHESChair: Rolland Benjamin (Bron, France, EU)

9:00 S01-1 GEORGES BROUSSE (Clermont-Ferrand, France, EU) - Type of Pain (Dolorosa) Matters: Physical or Mental, but the Human Partition Remains the Same

9:30 S01-2MAURICE DEMATTEIS (Grenoble, France, EU) - Addictive, Psychiatric and Pain Disorders: Different Clinical Expressions but Final Common Pathways

10:00 S01-3MARK KRAUS (New Haven, CT, USA) - Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder: Consensus and Controversies between European Pain and Addiction Specialists

Room A ⃝ 2 - POTENTIAL ADVANCES IN METHADONE-BASED TREATMENT FOR OPIOID USE DISORDERChair: Sergi Ferré (Baltimore, MD, USA)

9:00 S02-1SERGI FERRÉ (Baltimore, MD, USA) - Opioid-Galanin Receptor Heteromers Determine Weaker Dopaminergic Effects of Methadone as Compared to Morphine and Fentanyl

9:30 S02-2ANNABELLE BELCHER (Baltimore, Ml, USA) - Harnessing Placebo Effects to Augment Methadone Treatment Retention

10:00 S02-3DECLAN T. BARRY (New Haven, CT, USA) - Scale Up of Methadone Maintenance Treatment Using an Open-Access Model

Room B ⃝3 - DIFFERENT CLINICAL APPROACHES TO REACH PERSONS WITH OPIOID USE DISORDER; HOW TO BEST ADAPT TO CHANGING PATIENTS’ NEEDSChair: Thomas Clausen (Oslo, Norway) - Gabriele Fisher (Vienna, Austria, EU)

9:00 S03-1MARC AURIACOMBE (Bordeaux, France, EU) - The France Experience with Primary Care Level Provision of Buprenorphine for OUD as the Main Approach

9:20 SO3-2GABRIELE FISCHER (Vienna, Austria, EU) - Slow Release Oral Morphine (SROM) as the Preferred Treatment for OUD: The Austrian Experience

9:40 S03-3LARS TANUN (Oslo, Norway) - Long-Acting Injectable Partial Agonist and Antagonists: Promises and Pitfalls of Long-Acting Injectable for OUD

10:00 S03-4THOMAS CLAUSEN (Oslo, Norway) - A Range of Clinical Approaches to Reach Persons with Opioid Use Disorder Within One Clinic

Room C ⃝ 4 - VULNERABILITY TO ADDITIONChair: David Belin (Cambridge, Uk)

9:00 S04-1ALEJANDRO HIGUERA-MATAS (Valencia, Spain, EU) - Opioid Self-Administration Alters Brain Neurochemistry and Neural Plasticity Mediators: Modulation Following Withdrawal or Extinction.

9:20 S04-2LUCIA HIPOLITO (Madrid, Spain, EU) - Inflammatory Pain Induces Dysregulation of the KORS and MORS within Mesocorticolimbic System: Impact on Heroin and Alcohol Self-Administration

9:40 S04-3BENJAMIN BOUTREL (Prilly, Switzerland) - The Olievenstein’s broken mirror theory revisited: earlier life matters, how and why

10:00 S04-4DAVID BELIN (Cambridge, UK) - Behavioural and Neural Basis of the Individual Vulnerability to Develop Compulsive Heroin Seeking Habits

10:30 COFFEE BREAK

PlenaryRoom ⃝ Round Table - New perspectives of depot medications in Heroin Use Disorder

Chair: Icro Maremmani (Pisa, Italy)

11:00 PS4MICHAEL FROST (Conshohocken, PA, USA) - DAN LUBMAN (Richmond, Victoria, Australia) - VIJAY NADIPELLI (Richmond, VA, USA) - MAURICE DEMATTEIS (Grenoble, France,EU) - LORENZO SOMAINI (Biella, Italy, EU) -

13:00 CONFERENCE LUNCH



- 6 -


and timeABSTRACT

No


Chair: Jean-Pierre Daulouede (Bayonne, France, EU)

14:00 PL-4 MICHAEL FINGERHOOD (Baltimore, PA, USA) - Substance Use Disorders in Later Life


PlenaryRoom ⃝

5 - THE EUROPEAN ADDICTOVIGILANCE NETWORK: ROLE IN THE OPIOID EPIDEMICS AND IN OPIOID USE DISORDER WITH COMORBIDITIES (PAIN AND DUAL DISORDER)Chair: Michelle Mallaret (Grenoble, France, EU)

15:00 S05-1 MICHELLE MALLARET (Grenoble, France, EU) - The European Addictovigilance Network: Functioning and Role in the Epidemics of Opioid Substances and Their Regulation

15:30 S05-2 JOELLE MICALLEF (Marseille, France, EU) - Opioid Addiction in No-Cancer Chronic Pain Patients: Results from the French Addictovigilance Network

16:00 S05-3 MARYSE LAPEYRE-MESTRE (Toulose, France, EU) - Opioid Addiction in ADHD Patients: Results from the French Addictovigilance Network

Room A ⃝6 - USE OF PSYCHIATRIC MEDICATIONS IN DUAL DISORDER HEROIN USE DISORDER PATIENTS (in collaboration with World Association on Dual Disorder - WADD)Chair: Nestor Szerman (Madrid, Spain, Eu)

15:00 S06-1 NESTOR SZERMAN (Madrid, Spain, EU) - Opioid System and Mental Disorder

15:30 S06-2 ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Use of Psychiatric Medications in Dual Disorder (Heroin Use Disorder/Mood Disorders) Patients

16:00 S06-3 ICRO MAREMMANI (Pisa, Italy, EU) - Use of Psychiatric Medications in Dual Disorder (Heroin Use Disorder/Psychotic Disorder) Patients

Room B ⃝7 - SEEA NET SYMPOSIUM: PATIENTS TAILORED PROGRAMS - REALITY OR WISH (in collaboration with the South Eastern European and Adriatic Addiction Treatment Network)Chair: Andrej Kastelic (Ljubljana, Slovenia, Eu)

15:00 S07-1 ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Between Patients Needs, Expectations, Guidelines, Regulations and Law

15:30 S07-2 MIRJANA DELIC (Ljubljana, Slovenia, EU) - Different Dimensions of Wellness as a Part of Drug Addiction Treatment

16:00 S07-3 NUSA SEGREC (Ljubljana, Slovenia, Eu) - Treat or Not to Treat - Is This a Question?

Room C ⃝ 8 - SELECTED EUROPAD PRESENTATIONSChair: Matteo Pacini (Pisa,Italy, EU)

15:00 S08-1 MARC AURIACOMBE (Bordeaux, France, Eu) - Buprenorphine Dose, Craving and Opioid Use Severity in a Naturalistic Treatment Setting

15:30 S08-2 PAOLA ROSCA (Jerusalem, Israel) - Suboxone Film in Opioid Maintenance Treatment Centers: The Israeli Pilot Study Experience

16:00 S08-3 GABRIELLE KATRINE WELLE-STRAND (Oslo, Norway) - Somatic and Mental Health of Women in Opioid Maintenance Treatment (OMT) 10 Years after Their Child Was Born

16:30 COFFEE BREAK



- 7 -


and timeABSTRACT

No


Chair: - Jean Jacques Deglon (Geneve, Switzerland)

17:00 PL-5YIFRAH KAMINER (Farmington, CT, USA) - Determining Youth Intentional Lethal Opioids Over Dose: The Case of Psychological Autopsy to Complement the Medical Examiner Report


PlenaryRoom ⃝

9 - HARM REDUCTION AS A KEY PRINCIPLE FOR ACCESS TO CARE: INSIGHTS FROM THE SWISS-ROMANDY COLLEGE OF ADDICTION MEDICINEChair: Olivier Simon (Lausanne, France, EU)

18:00 S09-1 GERARD CALZADA (Geneve, Switzerland) - Prescription of Pharmaceutical Heroin Versus a Safe Place for Consumption

18:30 S09-2 OLIVIER SIMON (Lausanne, France) - Applying Risk and Harm Reduction to Gambling?

19:00 S09-3 DANIELE ZULLINO (Geneve, Switzerland) - From Heroin to Medical and No-Medical Cannabis

Room A ⃝10 - UNDERSTANDING THE CURRENT OPIOID CRISIS: GLOBAL CRISIS OF NO-MEDICAL USE OF OPIOIDSChair: Mercedes Lovrecic (Ljublijana, Slovenia, EU)

18:00 S10-1MERCEDES LOVRECIC ( Ljubljana, Slovenia, EU) - Outbreak of ‘Novel Synthetic Opioids’: No-Medical Use of Opioids

18:30 S10-2 MICHAEL J. BANNON (Detroit, MI, USA) - Decision Tree Analysis Reveals Recent Trends, Bio-markers, and Potential Drug Interactions Associated With Opioid Abuse

19:00 S10-3MAREN WRIGHT VOSS (Salt Lake City, UT, USA) - A Pain Education and Opioid Monitoring Program for a Community Setting: Creating Safety and Screening around Prescribed Opioids

Room B ⃝ 11 - INTEGRATED PSYCHIATRIC REHABILITATION FOR PATIENTS WITH DUAL DISORDERS: TOWARDS SOCIAL AND PERSONAL RECOVERYChair: Julien Dubreucq (St Martin d’Hères, France, EU)

18:00 S11-1 JULIEN DUBREUCQ (St Martin d’Hères, France, EU) - Recovery-Oriented Treatment for Patients with Dual Disorders in France: The Experience from Grenoble

18:30 S11-2 YASSER KHAZAAL ( Lausanne, Switzerland, EU) - Recovery-Oriented Treatment for Patients with Dual Disorders in Switzerland: The Experience from Lausanne

19:00 S11-3 KIM MUESER (Boston, MA, USA) - Recovery-Oriented Treatment for Patients with Dual Disorders in the USA: The Experience from Boston

Room C ⃝ 12- ADDICTION, INFECTIOUS DISEASES, ETHIC: HEALTHCARE IN PRISON Chair: Fadi Meroueh (Montpellier, France, EU)

18:00 S12-1 FADI MEROUEH (Montpellier, France, EU) - Elimination of Hepatitis C in Prison: Essential Combination Treatment with Harm Reduction

18:30 S12-2 ROBERT TELTZROW (Paris, France, EU) - New Psychoactive Substances in Prison – an Incalculable Risk for European Prisons?

19:00 S12-3 LINDA MONTANARI (Lisbon, Portugal, EU) - Drug Related Interventions in Europeans Prison: Evidence and Availability

20:30 SPEAKERs’ DINNER*

* Tickets are available for all delegates



- 8 -



- 9 -

SUNDAY NOVEMBER 21, 2021Room

and timeABSTRACT

No


PlenaryRoom ⃝ 13 - SUBSTANCE USE AND HUMAN RIGHTS

Chair: Marta Torrens (Barcelona, Catalonia, Spain)

9:00 S13-1 PETER KASTNER (Vienna, Austria, Eu) - Monitoring Human Rights Under the National Prevention Mechanism (NPM) Including Nelson Mandela Rules

9:30 S13-2 LINDA MONTANARI (Lisbon, Portugal, EU) - HCV in Europeans Prison in Persons with Drug Related Problems

10:00 S13-3 GABRIELE FISCHER (Vienna, Austria) - Hepatitis C and Attention-Deficit Hyperactivity Disorder in a High-Risk Group of Opioid-Maintained Prisoners

Room A ⃝ 14 - BENZODIAZEPINE USE AND ABUSE IN OPIOID AGONIST TREATMENTChair: Martin Haraldsen (Sandefjord, Norway)

9:00 S14-1MARTIN HARALDSEN (Sandefjord, Norway) - Benzodiazepine Stabilisation Treatment (BST) in Conjunction with Opioid Agonist Treatment (OAT): The Experience from a Norwegian Town General Practice Supporting BST

9:30 S14-2 ADAM BAKKER (London, Uk) - Benzodiazepine Maintenance in Opioid Agonist Treatment (OAT), Good or Bad?

10:00 S14-3 FERGUS LAW (Bath, Uk) - Opioid Overdose and a New Model of Drug Use and Tolerance with Implications for Treatment

Room B ⃝15 - METHADONE-ASSISTED PSYCHOTHERAPY (in collaboration with the Kantchelov Clinic)Chair: Alexander Kantchelov (Sofia, Bulgaria)

9:00 S15-1 RICK BES (Hilversum, Netherlands, EU) - Facilitating Change: Implementation of Mi (Motivational Interviewing) in Methadone-Assisted Psychotherapy

9:30 S15-2 TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - From Specific Psychopathology Towards Psychotherapeutic Strategies in Opioid Addiction Treatment

10:00 S15-3 ROBERT LAMBERT (Waterbury, Connecticut, USA) - Increasing Retention in Comprehensive Methadone Treatment by Integrating a Patient Centred Approach

10:30 COFFEE BREAK


Chair: Amine Benyamina (Paris, France, EU)

11:00 PL-6PIER PAOLO PANI (Cagliari, Italy, EU) - Unitary View of Psychopathology of Addiction. From Neurobiology to Clinical Perspective

12:00 PL-7IVAN MONTOYA (Rockville, Maryland, USA) - Therapeutic Perspective of Opioid Partial Agonists in Addiction Medicine and Psychiatric Disorders

13:00 Best poster Rovai Scholars award

13:15 ICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Pisa, Italy, in May 20-22, 2022!



- 10 -

⃝ POSTER SESSION

ABSTRACT No

P-01CHRISTER AAS (Bergen, Norway) - Quality of Life among People with Opioid Dependence: Results from a Multicenter Nested Cohort Study

P-02SEKER BURCU CETIN (Üsküdar, İstanbul Turkey) - Opioid Use of the Patients Who Have Both Addiction and a Risk of Ptsd in an Addiction Outpatient Counseling Center

P-03LARS T. FADNES (Bergen, Norway) - Effect of Integrated Treatment of Hepatitis C among People with Opioid Addiction: Results from a Multicenter Randomised Controlled Trial

P-04MOHAMED FARAH et al. (Massy, France, EU) - Risk-Adjusted Abstinence Rates Are Higher with Greater Buprenorphine Plasma Exposure among Patients Who Inject Opioids

P-05DIMY FLUYAU (Tyrone, GA, USA) - N-Methyl-D-Aspartate Receptor Antagonists for Opioid Dependence

P-06FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain) - A Multidisciplinary Approach to Treat Hepatitis C Infection in Heroin Addicted Patients

P-07FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain, EU) - Reaching the 90-90-90 UNAIDS Treatment Target for People Who Inject Drugs Receiving Integrated Clinical Care in a Drug Use Outpatient Treatment Facility

P-08ALLISON GALLANT ( Saint John, Canada) - Prevalence and Trends of Illicit Drug Use and Retention in a Low Threshold/High Tolerance Methadone Maintenance Treatment Program

P-09AARON GREENBLATT (Baltimore, MD, USA ) - Race-Based Differences in Self-Reported Drug Use at an Urban Methadone Treatment Program

P-10ZHANNA GAULEN et al. (Bergen, Norway) - Changes in Life Satisfaction among Opioid-Dependent Individuals Treated with Extended-Release Naltrexone or Buprenorphine-Naloxone

P-11MARGAUX KOSIM et al. (Paris, France, EU) - Patient Acceptance and Willingness to Use a New Formulation of Long Acting Buprenorphine- AMBRE Survey Results

P12JIMMY LANGLOIS et al. (Quebec, Canada) - Psychosocial outreach during outpatient low-barrier detoxification process with vulnerable people disaffiliated from formal health care system

P-13AMANDA LIBERMAN et al.(New Haven, CT, USA) - Decisional considerations for methadone uptake In Kyrgyz prisons

P-14MERCEDES LOVRECIC et al. (Ljubljana, Slovenia, EU) - The Filing of Addicted Patients at Addiction Units Is Correlated with a Reduction in Mortality Due to Illicit Opioids, but Also to Prescribed Opioids and Other Abused Substances

P-15NERMANA MEHIĆ-BASARA et al. (Sarajevo, Bosnia and Herzegovina) - Somatic Complications in Homeless Heroin Addict in the AOT Program - Case Report

P-16PASCAL MELIN et al. (Saint Dizier, France, EU ) - The Right Patient in the Right Way: “Road trip Hépatant”

P-17KALIA NIKOLAU (Limassol, Cyprus, EU) - The Role of Dynamic Inter-Family Characteristics in Drug Addiction

P-18WALTER PAGANIN et al. (Tivoli (RM), Itally, EU) - Depression Resistant to Antidepressant Medications or Depression Complicated by Hypophoria? (a Case Report)

P-19GABRIEL SHAYA et al. (Slough, UK ) - Reducing Relapse with Buprenorphine: Findings from the COSTEDOPIA & German Real-World Studies

P-20MARIA GIOVANNA TOCCO et al. (Milan, Italy, EU) - High Therapeutic Buprenorphine Levels Reduce Iv Fentanyl Respiratory Depression



- 11 -

P-21JOAN TRUJOLS et al. (Barcelona, Catalonia, Spain, EU) - Towards a Common Metric for Assessing Heroin-Dependent Patient Satisfaction with Medications: Satisfaction with Methadone as a Gold Standard?

P-22JOAN TRUJOLS et al. - Quality of Life and Well-Being from the Perspective of Patients on Opioid Agonist Maintenance Treatment: A Synthesis of Qualitative Research

P-23ALBRECHT ULMER (Stuttgart, Germany, EU) - Quintessence: What Have I Learned in the 30 Years of Treatment of Addicted Patients?

P-24 ALBRECHT ULMER (Stuttgart, Germany, EU) - The Nonsense and Crime of Prohibition

P-25GABRIEL VALLECILLO et al. (Barcelona, Catalonia, Spain, EU) - Increased Cardiovascular Risk among Older Adults with Heroin Use Disorder: A Comparative Study with the Population-Based REGICOR Cohort

P-26JORN HENRIK VOLD (Bergen, Norway) - Mental Health Symptoms among People with Opioid Dependence: Results from a Multicenter Nested Cohort Study



- 12 -



FacultyChrister AAS Department of Addiction Medicine, Haukeland University Hospital, Bergen,

Norway - [E-Mail: [email protected]]

Marc AURIACOMBE University of Bordeaux, Bordeaux, France, EU - [E-Mail: [email protected]]

Adam BAKKER Lisson Grove Health Centre, NHS, London, UK - [E-Mail: [email protected]]

Michael J. BANNON Wayne State University School of Medicine, Department of Pharmacology, Detroit, MI, USA - [E-Mail: [email protected]]

Declan T. BARRY Yale University School of Medicine, New Haven, CT, USA - [E-Mail: [email protected]]

Annabelle BELCHER University of Maryland School of Medicine, Baltimore, ML, USA - [E-Mail: [email protected]]

David BELIN University of Cambridge, Department of Psychology, Cambridge, UK - [E-Mail: [email protected]]

Rolland BENJAMIN Service Universitaire d’Addictologie de Lyon (SUAL), Ch Le Vinatier, Lyon University Hospital, Bron, France, EU - [E-Mail: [email protected]]

Rick BES Centre for Motivation and Change, ,Hilversum, Netherlands, EU - [E-Mail: [email protected]]

Roshan BHAD All India Institute of Medical Sciences (AIIMS), New Delhi, India - [E-Mail: [email protected]]

Benjamin BOUTREL Lab on the Neurobiology of Eating and Addictive Disorders, CHUV-Department of Psychiatry, Prilly, Switzerland - [E-Mail: [email protected]]

Georges BROUSSE Service Universitaire d’Addictologie de Lyon (SUAL), Ch Le Vinatier, Lyon University Hospital, Bron, France, EU - [E-Mail: [email protected]]

Seker BURCU CETIN Turkish Green Crescent Society Counseling Center, Üsküdar, İstanbul Turkey - [E-Mail: [email protected]; [email protected]]

Gerard CALZADA Service d'addictologie des HUG and College Romand de Médecine de l’Addiction, Geneve, Switzerland - [E-Mail: [email protected]]

Thomas CLAUSEN Oslo University Hospital, Oslo, Norway - [E-Mail: [email protected]]

Mirjana DELIC Ljubljana, Slovenia, EU - [E-Mail: [email protected]]

Filippo DELLA ROCCA School of Psychiatry, University of Pisa Pisa, Italy, EU - [E-Mail: [email protected]]

Maurice DEMATTEIS Grenoble Alpes University Hospital, Grenoble, France, EU, Grenoble, France, EU - [E-Mail: [email protected]]

Arun DHANDAYUDHAM Westminster Drug Project - WDP, London, UK - [E-Mail: [email protected]]

Julien DUBREUCQ Centre Référent de Réhabilitation Psychosociale et de Remédiation cognitive, St Martin d'Hères, France, EU - [E-Mail: [email protected]]

Peter ESPENSHADE Recovery Vermont, Montpelier, USA - [E-Mail: [email protected]]

Lars T. FADNES Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway - [E-Mail: [email protected]]

Mohamed FARAH Indivior France, Massy, France, EU - [E-Mail: [email protected]]

Sergi FERRÉ National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA - [E-Mail: [email protected]]

Michael FINGERHOOD Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Bayview Hospital Medical Center, Baltimora, Maryland, USA - [E-Mail: [email protected]]

- 13 -



Gabriele FISCHER Department for Psychiatry & Psychotherapy, Medical University Vienna, EU, Austria - [E-Mail: [email protected]]

Caterina FLORA Clinical Psychology, Paphos, Cyprus, EU, Paphos, Cyprus, EU - [E-Mail: [email protected]]

Dimy FLUYAU Emory University- School of Medicine, Tyrone, GA, USA - [E-Mail: [email protected]]

Francina FONSECAInstitute of Neuropsychiatry and Addictions (INAD), Hospital del Mar Medical Research Institute-IMIM. Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: [email protected]]

Michael FROST Frost Medical Group, Conshohocken, PA, USA - [E-Mail: [email protected]]

Allison GALLANT Dalhousie University, Horizon Health Network, Saint John, Canada, Saint John, Canada - [E-Mail: [email protected]]

Zhanna GAULENDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. The University of Bergen, Bergen, Norway - [E-Mail: [email protected]]

Aaron GREENBLATT University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: [email protected]]

Mark GILMAN Discovering Health Ltd, Manchester, UK - [E-Mail:

Zozan GULEKEN Üsküdar University , Istanbul, Turkey - [E-Mail: [email protected]]

Martin HARALDSEN Sandefjord, Norway - [E-Mail: [email protected]]

Alejandro HIGUERA-MATAS

Dpt. Farmàcia I Tec. Farmacèutica, Facultat Farmàcia, Universitat de València Valencia, Spain, EU - [E-Mail: [email protected]]

Lucia HIPOLITO Department of Psychobiology. School of Psychology. National University for Distance Learning (UNED), Madrid, Spain., EU - [E-Mail: [email protected]]

Liljana IGNJATOVA University Psychiatric Clinic, Skopje, North Macedonia - [E-Mail: [email protected]]

Zuzana KAMENDY Centre for Treatment of Drug Dependencies, Bratislava, Slovakia - [E-Mail: [email protected]]

Yifrah KAMINER Alcohol Research Ctr at the University of Connecticut Medical School, Farmington, CT, USA - [E-Mail: [email protected]]

Alexander KANTCHELOV The Kantchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: [email protected]]

Andrej KASTELIC Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana, Slovenia, EU - [E-Mail: [email protected]]

Peter KASTNER Ombudsmen Instiute, Vienna, Austria, EU - [E-Mail: [email protected]]

Yasser KHAZAAL Service de Médecine des Addictions, Lausanne, France, EU - [E-Mail: [email protected]]

Margaux KOSIM Consultation Addictologie Pass Hopital Pitié Salpètriere, Paris, Ile De France, France, EU - [E-Mail: [email protected]]

Mark KRAUS Yale University School of Medicine Connecticut, New Haven, CT, USA - [E-Mail: [email protected]]

Robert LAMBERT Connecticut Counseling Centers, Inc., Waterbury, Connecticut, USA - [E-Mail: [email protected]]

Jimmy LANGLOIS Université Laval, Québec, Canada - [E-Mail: [email protected]]

Maryse LAPEYRE-MESTRE

Addictovigilance, Toulose, France, EU - [E-Mail: [email protected]]

Fergus LAW University of Bristol, Bath, UK - [E-Mail: [email protected]]

- 14 -



Amanda LIBERMAN Yale University, New Haven, CT, USA

Mercedes LOVRECIC National Institute of Public Health, Ljubljana, Slovenia, EU, Ljubljana, Slovenia, EU - [E-Mail: [email protected]]

Dan LUBMAN Turning Point, Eastern Health and Monash Addiction Research Centre, Monash University, Richmond, Victoria, Australia - [E-Mail: [email protected]]

Michelle MALLARET Centre Addictovigilance CHU, Grenoble, France, EU - [E-Mail: [email protected]]

Angelo G. I. MAREMMANI

Department of Psychiatry, North-Western Tuscany Region NHS Local Health Unit, Viareggio, Italy, EU - [E-Mail: [email protected]]

Icro MAREMMANI Vincent P. Dole Dual Disorder Unit, 2nd Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: [email protected]]

Soraya MAYET Humber Teaching NHS FT, Hull, UK, Hull, UK - [E-Mail: [email protected]]

Nermana MEHIĆ-BASARA

Public Institute for Addiction Disorders of the Canton of Sarajevo, Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina - [E-Mail: [email protected]]

Pascal MELIN CHG Saint Dizier, Saint Dizier, France, EU Saint Dizier, France, EU - [E-Mail: [email protected]]

Fadi MEROUEH Health Without Barriers, France, EU - [E-Mail: [email protected]]

Joelle MICALLEF Addictovigilance, , Marseille, France, EU - [E-Mail: [email protected]]

Luke MITCHESON South London and Maudsley NHS Foundation Trust, London, UK - [E-Mail:

Linda MONTANARI EMCDDA, Lisbon, Portugal, EU - [E-Mail: [email protected]]

Ivan MONTOYA Division of Therapeutics and Medical Consequences (DTMC), NIDA, , Rockville, Maryland, USA - [E-Mail: [email protected]]

Kim MUESER Center for Psychiatric Rehabilitation,, Boston, MA, USA - [E-Mail: [email protected]]

Vijay NADIPELLI Indivior Inc., Richmond, VA , USA, Richmond, VA , USA - [E-Mail: [email protected]]

Kalia NIKOLAU University of Cyprus, Limassol, Cyprus, EU, Limassol, Cyprus, EU - [E-Mail: [email protected]]

Walter PAGANIN Department of Mental Health ASL RM/5, Tivoli (RM), Itally, EU - [E-Mail: [email protected]]

Pier Paolo PANI Social-Health Services, Health District USL Cagliari, Italy, EU - [E-Mail: [email protected]]

Mark PARRINO Americam Association for the Treatment of Opioid dependence, New York, New York, USA - [E-Mail: [email protected]]

Lucie PENNEL Service Universitaire de Pharmaco-Addictologie-CSAPA, CHU Grenoble Alpes, Saint-Martin d'Hères, France, EU - [E-Mail: [email protected]]

Marc REISINGER European Opioid Addiction Treatment Association, Brussels, Belgium, EU - [E-Mail: [email protected]]

Marco RIGLIETTA Addiction Medicine Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy, EU - [E-Mail: [email protected]]

Paola ROSCA National Supervisor, Dept for the Treatment of Substance Abuse Ministry of Health, Jerusalem, Israel - [E-Mail: [email protected]]

Perrine ROUXAix Marseille University, INSERM, IRD, SESSTIM, ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France, EU - [E-Mail: [email protected].]

Nusa SEGREC Center for treatment of drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU - [E-Mail: [email protected]]

- 14 - - 15 -



Gabriel SHAYA Indivior, Slough, UK - [E-Mail: [email protected]]

Olivier SIMON Centre du Jeu Excessif, CHUV, Lausanne Et Collège Romand de Médecine de L'addiction, Lausanne, France - [E-Mail: [email protected]]

Lorenzo SOMAINI Drug Addiction Unit, Biella, Italy, EU - [E-Mail: [email protected]]

Tsvetana STOYKOVA The Kantchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: [email protected]]

Sir John STRANG National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, London UK - [E-Mail: [email protected]]

Nestor SZERMAN Complutense University of Madrid, Spain, EU, Madrid, Spain, EU - [E-Mail: [email protected]]

Lars TANUN Oslo University Hospital, , Oslo, Norway - [E-Mail: [email protected]]

Robert TELTZROW Consultant Pompidou Group of the Council of Europe, Paris, France, EU - [E-Mail: [email protected]]

Maria Giovanna TOCCO Indivior Italia, Milan, Italy, EU - [E-Mail: [email protected]]

Marta TORRENSAddiction Unit, Institute of Psychiatry and Addictions, Hospital del Mar-IMIM, University of Barcelona, Barcelona, Catalonia, Spain, EU - [E-Mail: [email protected]]

Joan TRUJOLSHospital de la Santa Cruz and Sant Pau / Sant Pau Biomedical Research Institute (IIB Sant Pau) / CIBER Mental Health (CIBERSAM), Barcelona, Catalonia, Spain,EU - [E-Mail: [email protected]]

Albrecht ULMER Institute for addiction research, Stuttgart, Germany, EU - [E-Mail: [email protected]]

Gabriel VALLECILLOInstitute of Neuropsychiatry and Addictions (INAD). Hospital del Mar Medical Research Institute-IMIM, Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: [email protected]]

Jorn Henrik VOLD Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway, Bergen, Norway - [E-Mail: [email protected]]

Maren Wright VOSS Utah State University Extension, South Jordan, UT, USA, Salt Lake City, UT, USA - [E-Mail: [email protected]]

Gabrielle Katrine WELLE-STRAND

Norwegian Centre for Addiction Research (Seraf), University of Oslo, Oslo, Norway - [E-Mail: [email protected]]

Daniele ZULLINO Service d'addictologie des hôpitaux universitaires de Genève et Collège romand de médecine de l'addiction, Geneve, Switzerland - [E-Mail: [email protected]]

- 16 -

Former recipients:Marc Auriacombe (France) - 2002 Vladimir Mendelevich (Russia) - 2014Olof Blix (Sweden) - 2000 Lubomir Okruhlica (Slovak Republic) - 2002Miguel Casas (Spain) - 2012 Matteo Pacini (Italy) - 2018Thomas Clausen (Norway) -2014 Pier Paolo Pani (Italy) - 2004Pascal Courty (France) -2012 Luis Patricio (Portugal) -2010Jean-Jacques Deglon (Switzerland) - 2004 Einat Peles (Israel) -2016Maurice Dematteis (France) - 2018 Slavko Sakoman (Croatia) - 2010Sergey Dvoryak (Ukraine) -2010 Lorenzo Somaini (Italy) - 2014Gabriele Fischer (Austria) - 2008 Marta Torrens (Spain) - 2006Gilberto Gerra (Italy) - 2006 Didier Touzeau (France) - 2008Ante Ivancic (Croatia) - 2006 Ambros Uchtenhagen (Switzerland) - 2016Alexander Kantchelov (Bulgaria) - 2004 Peter Vossenberg (The Netherlands) - 2016Andrej Kastelic (Slovenia) - 2008 Helge Waal (Norway) - 2012Mercedes Lovrecic (Slovenia) - 2002 Gabrielle Welle-Strand (Norway) - 2018Former career award recipients: Jean-Pierre Daulouede (France) - 2016 Robert Newman (USA) - 2012Loretta Finnegan (USA) - 2010 Marc Reisinger (Belgium) - 2004Mary Jeanne Kreek (USA) - 2014 Mark Parrino (USA) - 2018Joyce Lowinson (USA) - 2007 Alessandro Tagliamonte (Italy) - 2004Icro Maremmani (Italy) - 2004

“The Luca Rovai Award”

“Dedicated to all those who dream of a better world for drug addicts”

PISA-School of Clinical and Experimental Psychiatry

ROVAI SCHOLARS AWARDROVAI SCHOLARS AWARDAssociation for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS)

AU-CNSAssociation for the Application of Neuroscientific

Knowledge to Social Aims

Helping people to understand neuroscientific update

Former recipients:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Marem-mani. Poster presented at New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives” Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R.V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen. Poster presented at 2° World Congress of the World Association on Dual Disorders (WADD), Florence, October 25-27 2018

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tri-podi, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi. Poster presented at Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders, Pisa, Italy, EU, July, 8-9 2019

Rovai Scholars award, named after one of the founding member of PISA-School of Experimental and Clinical Psychiatry Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Ex-perimental and Clinical Psychiatry and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

PLAT

INU

M S

PON

SORS

Cam

urus

Indi

vior

Mol

teni

BRO

NZE

SPO

NSO

RBo

ucha

ra-R

ecor

dati

OTH

ER S

PON

SOR

Ethy

phar

m

Und

er th

e Pa

tron

age

of

Wor

ld F

eder

ation

for t

he T

reat

men

t of O

pioi

d De

pend

ence

, N

ew Y

ork,

NY,

USA

U

nive

rsity

of G

reno

ble,

Fra

nce,

EU

Fédé

ratio

n Fr

ança

ise

d’Ad

dict

olog

ieM

issi

on in

term

inis

térie

lle d

e lu

tte

cont

re le

s dro

gues

et l

es

cond

uite

s add

ictiv

es

Féde

ratio

n Ad

dicti

on

heroin addiction & related clinical problems

Documents